BioView Named Fastest Growing Life Sciences Company in Deloitte Fast 500 EMEA

REHOVOT, Israel, November 27 /PRNewswire-FirstCall/ -- BioView Ltd. (TASE:BIOV) today announced that it ranked number 1 in the 2006 Deloitte Technology Fast 500 EMEA for the Life Sciences/Biotech sector and number 38 in the total Fast 500 EMEA program. The 2006 Deloitte Technology Fast 500 EMEA, ranks the 500 fastest growing technology companies in Europe, Middle East and Africa. Rankings are based on percentage revenue growth over five years, from 2002-2006.

BioView's automated scanning microscope and image analysis systems perform a wide range of genetic tests based on fluorescent in situ hybridization (FISH) technology with applications in cancer screening and diagnosis, prenatal and post-natal genetic analysis and minimal residual disease. The BioView instruments help commercial and hospital laboratories provide highly reliable test results to physicians and patients quickly and cost-effectively and also are used in advanced research.

Commenting on the award, BioView's President and CEO Dr. Opher Shapira said, "We are proud to be included in the Deloitte Fast 500 and thank them for their recognition. This ranking is a tribute to the dedicated employees of BioView who developed and succeeded in successfully marketing and supporting our advanced technology platform. Our continued technological innovation and superior customer support have helped us achieve a leadership position in automated FISH testing in commercial and research laboratories. We intend to build on this platform as we begin to focus our efforts on the development of new diagnostic tests for this industry."

"Making the Deloitte Technology Fast 500 EMEA ranking is a testament to a company's commitment to technology," Eric Morgain, partner in charge of Deloitte's Technology Fast 500 EMEA program. "With its high growth rate over five years, BioView has proven that its leadership has the vision and determination to grow in difficult conditions."

About BioView Ltd.

Established in 2000, and led by an expert team of biologists, software engineers and physicists, BioView develops, manufactures and supplies cell imaging equipment, biological kits and software to medical institutes and universities. BioView is a publicly traded company on the Israeli Stock exchange, and currently has strategic collaborations underway with international scientific leaders and institutions.

About Deloitte

Deloitte refers to one or more of Deloitte Touche Tohmatsu, a Swiss Verein, its member firms, and their respective subsidiaries and affiliates. Deloitte Touche Tohmatsu is an organization of member firms around the world devoted to excellence in providing professional services and advice, focused on client service through a global strategy executed locally in over 140 countries. With access to the deep intellectual capital of approximately 150,000 people worldwide, Deloitte delivers services in four professional areas - audit, tax, consulting, and financial advisory services - and serves more than 80 percent of the world's largest companies, as well as large national enterprises, public institutions, locally important clients, and successful, fast-growing global companies. Services are not provided by the Deloitte Touche Tohmatsu Verein, and, for regulatory and other reasons, certain member firms do not provide services in all four professional areas. As a Swiss Verein (association), neither Deloitte Touche Tohmatsu nor any of its member firms has any liability for each other's acts or omissions. Each of the member firms is a separate and independent legal entity operating under the names "Deloitte," "Deloitte & Touche," "Deloitte Touche Tohmatsu," or other related names.

For more information about the BioView technology, and press related issues, please contact opher@bioview.co.il or visit our website at http://www.bioview.co.il

CONTACT: For more information about the BioView technology, and press
related issues, please contact opher@bioview.co.il or visit our website at
http://www.bioview.co.il

Back to news